Interleukin-10 and interleukin-1 receptor antagonist distinguish between patients with sepsis and the systemic inflammatory response syndrome (SIRS)
- PMID: 31125901
- DOI: 10.1016/j.cyto.2019.05.015
Interleukin-10 and interleukin-1 receptor antagonist distinguish between patients with sepsis and the systemic inflammatory response syndrome (SIRS)
Abstract
The current study evaluated the potential of clinical parameters and circulating biomarkers to distinguish sepsis from SIRS in patients admitted with systemic inflammation. Clinical parameters, leukocyte counts and platelets were measured on admission. Circulating C-reactive protein (CRP), procalcitonin (PCT) and cytokine concentrations were quantified using laser immunonephelometry, immunoluminescence and a Bio-Plex suspension bead array system respectively. Blood, sputum, urine, peritoneal and cerebrospinal fluid were sent for microscopy and culture. Based on clinical information and the results of microbiological testing, 62 patients were classified retrospectively into 2 groups, those with sepsis (n = 37) or SIRS (n = 25). Mean body temperature was higher and blood pressure lower in the sepsis patients. Circulating concentrations of CRP, PCT, interleukin (IL)-10 and IL-1 receptor antagonist (IL-1Ra) were significantly higher in patients with sepsis, with IL-10 identified as the best biomarker in differentiating sepsis from SIRS. The biomarkers that best predicted overall mortality were platelet counts >PCT ≥ CRP > IL-6 > IL-1Ra. These findings demonstrate that patients with sepsis have significantly increased levels of the immunosuppressive/anti-inflammatory cytokines, IL-1Ra and IL-10, compared to those with SIRS, consistent with a more intense counteracting anti-inflammatory response, while a biomarker profile including platelets, PCT, CRP, IL-6 and IL-1Ra may be useful to predict mortality.
Keywords: Biomarkers; Inflammation and cytokines; SIRS; Sepsis.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6.Crit Care Med. 2000 Aug;28(8):2793-8. doi: 10.1097/00003246-200008000-00019. Crit Care Med. 2000. PMID: 10966252
-
Procalcitonin as a rapid diagnostic biomarker to differentiate between culture-negative bacterial sepsis and systemic inflammatory response syndrome: a prospective, observational, cohort study.J Crit Care. 2015 Feb;30(1):218.e7-12. doi: 10.1016/j.jcrc.2014.08.017. Epub 2014 Sep 6. J Crit Care. 2015. PMID: 25263339
-
The diagnostic ability of procalcitonin and interleukin-6 to differentiate infectious from noninfectious systemic inflammatory response syndrome and to predict mortality.J Crit Care. 2016 Jun;33:245-51. doi: 10.1016/j.jcrc.2016.01.002. Epub 2016 Jan 7. J Crit Care. 2016. PMID: 26851139
-
Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome.Cytokine. 2016 Dec;88:126-135. doi: 10.1016/j.cyto.2016.08.033. Epub 2016 Sep 4. Cytokine. 2016. PMID: 27599258 Review.
-
Inflammatory markers in SIRS, sepsis and septic shock.Curr Med Chem. 2008;15(6):581-7. doi: 10.2174/092986708783769704. Curr Med Chem. 2008. PMID: 18336272 Review.
Cited by
-
Early serum biomarkers to characterise different phenotypes of primary graft dysfunction after lung transplantation: a systematic scoping review.ERJ Open Res. 2024 Aug 5;10(4):00121-2024. doi: 10.1183/23120541.00121-2024. eCollection 2024 Jul. ERJ Open Res. 2024. PMID: 39104958 Free PMC article.
-
The Surviving Sepsis Campaign: Basic/Translational Science Research Priorities.Crit Care Med. 2020 Aug;48(8):1217-1232. doi: 10.1097/CCM.0000000000004408. Crit Care Med. 2020. PMID: 32697495 Free PMC article.
-
The surviving sepsis campaign: basic/translational science research priorities.Intensive Care Med Exp. 2020 Jul 17;8(1):31. doi: 10.1186/s40635-020-00312-4. Intensive Care Med Exp. 2020. PMID: 32676795 Free PMC article.
-
Clinical and biological markers for predicting ARDS and outcome in septic patients.Sci Rep. 2021 Nov 22;11(1):22702. doi: 10.1038/s41598-021-02100-w. Sci Rep. 2021. PMID: 34811434 Free PMC article.
-
Dynamic monitoring of kidney injury status over 3 days in the intensive care unit as a sepsis phenotype associated with hospital mortality and hyperinflammation.Biomed J. 2022 Aug;45(4):665-674. doi: 10.1016/j.bj.2021.08.006. Epub 2021 Sep 3. Biomed J. 2022. PMID: 34482015 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous